Human Clinical Trials (future)
the next step in the evolution of RadioGel™ – Precision Radionuclide Therapy (PRnT)
Human Clinical Trials
We're actively engaged with the USA FDA on our Pre-Submission Investigational Device Exemption for RadioGel™. Once the completed application is finalized, and submited;
upon approval we're planning to begin by treating thyroid cancer lymph nodes.
RadioGel™ is a precision radionuclide therapy device for delivering therapeutic radiation into solid metastatic tumors in the lymph nodes associated with papillary thyroid cancer
which are accessible by percutaneous direct needle injection in patients who are not surgical candidates or who have declined surgery.
Updates Contact
Home Page Cover Image:
Veterinarian Dr. Michelle Myer from Vista Veterinarian Hospital in Kennewick, WA.
Seen here administering IsoPet® therapy to a feline suffering from a sarcoma.
RadioGel™ is a hydrogel liquid containing tiny yttrium-90 (90Y) phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.
IsoPet® Therapy Application(s)
Precision Radionuclide Therapy (PRnT)
Vivos Inc. - (OTCQB: RDGL) Investor Relations
Contact
| bg-primary | |
| bg-primary-light | |
| bg-primary-dark | |
| bg-secondary | |
| bg-secondary-dark |
| body | |
| top-header | |
| header | |
| content |
| background | |
| text color | |
| link color | |
| horizontal line |
| style 1 | |
| style 2 | |
| style 3 |
| social icons | |
| navigation color | |
| subnav background |
| background color | |
| navigation color |
Note: All changes made here will be applied to your entire website.
